Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience
This multi-institutional registry study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (DMPM). A multi-institutional data registry that included 405 patients with DMPM treated by a uniform approach t...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2009-12, Vol.27 (36), p.6237-6242 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6242 |
|---|---|
| container_issue | 36 |
| container_start_page | 6237 |
| container_title | Journal of clinical oncology |
| container_volume | 27 |
| creator | Yan, Tristan D Deraco, Marcello Baratti, Dario Kusamura, Shigeki Elias, Dominique Glehen, Olivier Gilly, François N Levine, Edward A Shen, Perry Mohamed, Faheez Moran, Brendan J Morris, David L Chua, Terence C Piso, Pompiliu Sugarbaker, Paul H |
| description | This multi-institutional registry study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (DMPM).
A multi-institutional data registry that included 405 patients with DMPM treated by a uniform approach that used CRS and HIPEC was established. The primary end point was overall survival. The secondary end point was evaluation of prognostic variables for overall survival.
Follow-up was complete in 401 patients (99%). The median follow-up period for the patients who were alive was 33 months (range, 1 to 235 months). The mean age was 50 years (standard deviation [SD], 14 years). Three hundred eighteen patients (79%) had epithelial tumors. Twenty-five patients (6%) had positive lymph nodes. The mean peritoneal cancer index was 20. One hundred eighty-seven patients (46%) had complete or near-complete cytoreduction. Three hundred seventy-two patients (92%) received HIPEC. One hundred twenty-seven patients (31%) had grades 3 to 4 complications. Nine patients (2%) died perioperatively. The mean length of hospital stay was 22 days (SD, 15 days). The overall median survival was 53 months (1 to 235 months), and 3- and 5-year survival rates were 60% and 47%, respectively. Four prognostic factors were independently associated with improved survival in the multivariate analysis: epithelial subtype (P < .001), absence of lymph node metastasis (P < .001), completeness of cytoreduction scores of CC-0 or CC-1 (P < .001), and HIPEC (P = .002).
The data suggest that CRS combined with HIPEC achieved prolonged survival in selected patients with DMPM. |
| doi_str_mv | 10.1200/JCO.2009.23.9640 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734200943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734200943</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-3e7984a05e8fe1116948240d3af067514bcf7e2ae95ba9a395d2d71f06078f773</originalsourceid><addsrcrecordid>eNpFkE1v1DAQhi1ERZfCnRPyjVMWfyWOuaGo0EVdFQkq9WZ5k8muKydebKc0P4F_jaOutKfRaJ73HelB6AMla8oI-fyjuVvnqdaMr1UlyCu0oiWThZRl-RqtiOSsoDV_uERvY3wkhIqal2_QJVWKyrpiK_SvmZMP0E1tsk-Af01hD2HGZuzwzXyEkA4QBtvizZiCybtNfgTjcHOAwS9Hc5xx7wPeGmf3oxkT_nmmthAXyFk_mC94O7lki80Yk01Tsn7MxPXzUgpjC-_QRW9chPeneYXuv13_bm6K27vvm-brbdEKXqeCg1S1MKSEugdKaaVEzQTpuOlJJUsqdm0vgRlQ5c4ow1XZsU7SfCSy7qXkV-jTS-8x-D8TxKQHG1twzozgp6glF4tSwTNJXsg2-BgD9PoY7GDCrCnRi3-d_esF1ozrxX-OfDyVT7sBunPgJPz8_WD3h782gI6DcS7jTD-2nknNK505yf8DOdWRmA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734200943</pqid></control><display><type>article</type><title>Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Yan, Tristan D ; Deraco, Marcello ; Baratti, Dario ; Kusamura, Shigeki ; Elias, Dominique ; Glehen, Olivier ; Gilly, François N ; Levine, Edward A ; Shen, Perry ; Mohamed, Faheez ; Moran, Brendan J ; Morris, David L ; Chua, Terence C ; Piso, Pompiliu ; Sugarbaker, Paul H</creator><creatorcontrib>Yan, Tristan D ; Deraco, Marcello ; Baratti, Dario ; Kusamura, Shigeki ; Elias, Dominique ; Glehen, Olivier ; Gilly, François N ; Levine, Edward A ; Shen, Perry ; Mohamed, Faheez ; Moran, Brendan J ; Morris, David L ; Chua, Terence C ; Piso, Pompiliu ; Sugarbaker, Paul H</creatorcontrib><description>This multi-institutional registry study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (DMPM).
A multi-institutional data registry that included 405 patients with DMPM treated by a uniform approach that used CRS and HIPEC was established. The primary end point was overall survival. The secondary end point was evaluation of prognostic variables for overall survival.
Follow-up was complete in 401 patients (99%). The median follow-up period for the patients who were alive was 33 months (range, 1 to 235 months). The mean age was 50 years (standard deviation [SD], 14 years). Three hundred eighteen patients (79%) had epithelial tumors. Twenty-five patients (6%) had positive lymph nodes. The mean peritoneal cancer index was 20. One hundred eighty-seven patients (46%) had complete or near-complete cytoreduction. Three hundred seventy-two patients (92%) received HIPEC. One hundred twenty-seven patients (31%) had grades 3 to 4 complications. Nine patients (2%) died perioperatively. The mean length of hospital stay was 22 days (SD, 15 days). The overall median survival was 53 months (1 to 235 months), and 3- and 5-year survival rates were 60% and 47%, respectively. Four prognostic factors were independently associated with improved survival in the multivariate analysis: epithelial subtype (P < .001), absence of lymph node metastasis (P < .001), completeness of cytoreduction scores of CC-0 or CC-1 (P < .001), and HIPEC (P = .002).
The data suggest that CRS combined with HIPEC achieved prolonged survival in selected patients with DMPM.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2009.23.9640</identifier><identifier>PMID: 19917862</identifier><language>eng</language><publisher>United States: American Society of Clinical Oncology</publisher><subject>Antineoplastic Agents - administration & dosage ; Combined Modality Therapy ; Female ; Humans ; Hyperthermia, Induced - methods ; Infusions, Parenteral ; Male ; Mesothelioma - drug therapy ; Mesothelioma - pathology ; Mesothelioma - surgery ; Mesothelioma - therapy ; Middle Aged ; Peritoneal Neoplasms - drug therapy ; Peritoneal Neoplasms - pathology ; Peritoneal Neoplasms - surgery ; Peritoneal Neoplasms - therapy ; Prognosis ; Survival Rate</subject><ispartof>Journal of clinical oncology, 2009-12, Vol.27 (36), p.6237-6242</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-3e7984a05e8fe1116948240d3af067514bcf7e2ae95ba9a395d2d71f06078f773</citedby><cites>FETCH-LOGICAL-c438t-3e7984a05e8fe1116948240d3af067514bcf7e2ae95ba9a395d2d71f06078f773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3716,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19917862$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yan, Tristan D</creatorcontrib><creatorcontrib>Deraco, Marcello</creatorcontrib><creatorcontrib>Baratti, Dario</creatorcontrib><creatorcontrib>Kusamura, Shigeki</creatorcontrib><creatorcontrib>Elias, Dominique</creatorcontrib><creatorcontrib>Glehen, Olivier</creatorcontrib><creatorcontrib>Gilly, François N</creatorcontrib><creatorcontrib>Levine, Edward A</creatorcontrib><creatorcontrib>Shen, Perry</creatorcontrib><creatorcontrib>Mohamed, Faheez</creatorcontrib><creatorcontrib>Moran, Brendan J</creatorcontrib><creatorcontrib>Morris, David L</creatorcontrib><creatorcontrib>Chua, Terence C</creatorcontrib><creatorcontrib>Piso, Pompiliu</creatorcontrib><creatorcontrib>Sugarbaker, Paul H</creatorcontrib><title>Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>This multi-institutional registry study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (DMPM).
A multi-institutional data registry that included 405 patients with DMPM treated by a uniform approach that used CRS and HIPEC was established. The primary end point was overall survival. The secondary end point was evaluation of prognostic variables for overall survival.
Follow-up was complete in 401 patients (99%). The median follow-up period for the patients who were alive was 33 months (range, 1 to 235 months). The mean age was 50 years (standard deviation [SD], 14 years). Three hundred eighteen patients (79%) had epithelial tumors. Twenty-five patients (6%) had positive lymph nodes. The mean peritoneal cancer index was 20. One hundred eighty-seven patients (46%) had complete or near-complete cytoreduction. Three hundred seventy-two patients (92%) received HIPEC. One hundred twenty-seven patients (31%) had grades 3 to 4 complications. Nine patients (2%) died perioperatively. The mean length of hospital stay was 22 days (SD, 15 days). The overall median survival was 53 months (1 to 235 months), and 3- and 5-year survival rates were 60% and 47%, respectively. Four prognostic factors were independently associated with improved survival in the multivariate analysis: epithelial subtype (P < .001), absence of lymph node metastasis (P < .001), completeness of cytoreduction scores of CC-0 or CC-1 (P < .001), and HIPEC (P = .002).
The data suggest that CRS combined with HIPEC achieved prolonged survival in selected patients with DMPM.</description><subject>Antineoplastic Agents - administration & dosage</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperthermia, Induced - methods</subject><subject>Infusions, Parenteral</subject><subject>Male</subject><subject>Mesothelioma - drug therapy</subject><subject>Mesothelioma - pathology</subject><subject>Mesothelioma - surgery</subject><subject>Mesothelioma - therapy</subject><subject>Middle Aged</subject><subject>Peritoneal Neoplasms - drug therapy</subject><subject>Peritoneal Neoplasms - pathology</subject><subject>Peritoneal Neoplasms - surgery</subject><subject>Peritoneal Neoplasms - therapy</subject><subject>Prognosis</subject><subject>Survival Rate</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1v1DAQhi1ERZfCnRPyjVMWfyWOuaGo0EVdFQkq9WZ5k8muKydebKc0P4F_jaOutKfRaJ73HelB6AMla8oI-fyjuVvnqdaMr1UlyCu0oiWThZRl-RqtiOSsoDV_uERvY3wkhIqal2_QJVWKyrpiK_SvmZMP0E1tsk-Af01hD2HGZuzwzXyEkA4QBtvizZiCybtNfgTjcHOAwS9Hc5xx7wPeGmf3oxkT_nmmthAXyFk_mC94O7lki80Yk01Tsn7MxPXzUgpjC-_QRW9chPeneYXuv13_bm6K27vvm-brbdEKXqeCg1S1MKSEugdKaaVEzQTpuOlJJUsqdm0vgRlQ5c4ow1XZsU7SfCSy7qXkV-jTS-8x-D8TxKQHG1twzozgp6glF4tSwTNJXsg2-BgD9PoY7GDCrCnRi3-d_esF1ozrxX-OfDyVT7sBunPgJPz8_WD3h782gI6DcS7jTD-2nknNK505yf8DOdWRmA</recordid><startdate>20091220</startdate><enddate>20091220</enddate><creator>Yan, Tristan D</creator><creator>Deraco, Marcello</creator><creator>Baratti, Dario</creator><creator>Kusamura, Shigeki</creator><creator>Elias, Dominique</creator><creator>Glehen, Olivier</creator><creator>Gilly, François N</creator><creator>Levine, Edward A</creator><creator>Shen, Perry</creator><creator>Mohamed, Faheez</creator><creator>Moran, Brendan J</creator><creator>Morris, David L</creator><creator>Chua, Terence C</creator><creator>Piso, Pompiliu</creator><creator>Sugarbaker, Paul H</creator><general>American Society of Clinical Oncology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20091220</creationdate><title>Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience</title><author>Yan, Tristan D ; Deraco, Marcello ; Baratti, Dario ; Kusamura, Shigeki ; Elias, Dominique ; Glehen, Olivier ; Gilly, François N ; Levine, Edward A ; Shen, Perry ; Mohamed, Faheez ; Moran, Brendan J ; Morris, David L ; Chua, Terence C ; Piso, Pompiliu ; Sugarbaker, Paul H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-3e7984a05e8fe1116948240d3af067514bcf7e2ae95ba9a395d2d71f06078f773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antineoplastic Agents - administration & dosage</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperthermia, Induced - methods</topic><topic>Infusions, Parenteral</topic><topic>Male</topic><topic>Mesothelioma - drug therapy</topic><topic>Mesothelioma - pathology</topic><topic>Mesothelioma - surgery</topic><topic>Mesothelioma - therapy</topic><topic>Middle Aged</topic><topic>Peritoneal Neoplasms - drug therapy</topic><topic>Peritoneal Neoplasms - pathology</topic><topic>Peritoneal Neoplasms - surgery</topic><topic>Peritoneal Neoplasms - therapy</topic><topic>Prognosis</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yan, Tristan D</creatorcontrib><creatorcontrib>Deraco, Marcello</creatorcontrib><creatorcontrib>Baratti, Dario</creatorcontrib><creatorcontrib>Kusamura, Shigeki</creatorcontrib><creatorcontrib>Elias, Dominique</creatorcontrib><creatorcontrib>Glehen, Olivier</creatorcontrib><creatorcontrib>Gilly, François N</creatorcontrib><creatorcontrib>Levine, Edward A</creatorcontrib><creatorcontrib>Shen, Perry</creatorcontrib><creatorcontrib>Mohamed, Faheez</creatorcontrib><creatorcontrib>Moran, Brendan J</creatorcontrib><creatorcontrib>Morris, David L</creatorcontrib><creatorcontrib>Chua, Terence C</creatorcontrib><creatorcontrib>Piso, Pompiliu</creatorcontrib><creatorcontrib>Sugarbaker, Paul H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Tristan D</au><au>Deraco, Marcello</au><au>Baratti, Dario</au><au>Kusamura, Shigeki</au><au>Elias, Dominique</au><au>Glehen, Olivier</au><au>Gilly, François N</au><au>Levine, Edward A</au><au>Shen, Perry</au><au>Mohamed, Faheez</au><au>Moran, Brendan J</au><au>Morris, David L</au><au>Chua, Terence C</au><au>Piso, Pompiliu</au><au>Sugarbaker, Paul H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2009-12-20</date><risdate>2009</risdate><volume>27</volume><issue>36</issue><spage>6237</spage><epage>6242</epage><pages>6237-6242</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>This multi-institutional registry study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (DMPM).
A multi-institutional data registry that included 405 patients with DMPM treated by a uniform approach that used CRS and HIPEC was established. The primary end point was overall survival. The secondary end point was evaluation of prognostic variables for overall survival.
Follow-up was complete in 401 patients (99%). The median follow-up period for the patients who were alive was 33 months (range, 1 to 235 months). The mean age was 50 years (standard deviation [SD], 14 years). Three hundred eighteen patients (79%) had epithelial tumors. Twenty-five patients (6%) had positive lymph nodes. The mean peritoneal cancer index was 20. One hundred eighty-seven patients (46%) had complete or near-complete cytoreduction. Three hundred seventy-two patients (92%) received HIPEC. One hundred twenty-seven patients (31%) had grades 3 to 4 complications. Nine patients (2%) died perioperatively. The mean length of hospital stay was 22 days (SD, 15 days). The overall median survival was 53 months (1 to 235 months), and 3- and 5-year survival rates were 60% and 47%, respectively. Four prognostic factors were independently associated with improved survival in the multivariate analysis: epithelial subtype (P < .001), absence of lymph node metastasis (P < .001), completeness of cytoreduction scores of CC-0 or CC-1 (P < .001), and HIPEC (P = .002).
The data suggest that CRS combined with HIPEC achieved prolonged survival in selected patients with DMPM.</abstract><cop>United States</cop><pub>American Society of Clinical Oncology</pub><pmid>19917862</pmid><doi>10.1200/JCO.2009.23.9640</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2009-12, Vol.27 (36), p.6237-6242 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734200943 |
| source | MEDLINE; American Society of Clinical Oncology Online Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antineoplastic Agents - administration & dosage Combined Modality Therapy Female Humans Hyperthermia, Induced - methods Infusions, Parenteral Male Mesothelioma - drug therapy Mesothelioma - pathology Mesothelioma - surgery Mesothelioma - therapy Middle Aged Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - pathology Peritoneal Neoplasms - surgery Peritoneal Neoplasms - therapy Prognosis Survival Rate |
| title | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T03%3A14%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytoreductive%20Surgery%20and%20Hyperthermic%20Intraperitoneal%20Chemotherapy%20for%20Malignant%20Peritoneal%20Mesothelioma:%20Multi-Institutional%20Experience&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=Yan,%20Tristan%20D&rft.date=2009-12-20&rft.volume=27&rft.issue=36&rft.spage=6237&rft.epage=6242&rft.pages=6237-6242&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2009.23.9640&rft_dat=%3Cproquest_cross%3E734200943%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734200943&rft_id=info:pmid/19917862&rfr_iscdi=true |